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INTRODUCTION
Ibuprofen belongs to the group of nonsteroidal 
anti-inflammatory drugs (NSAID) used to treat 
diverse inflammatory processes, pain, or fever. 
The mechanism underlying the effects of 
ibuprofen stems from the inhibition of 
cyclooxygenase (COX) activity, which is required 
for prostaglandin (PG) synthesis.1 PG are 
produced from plasma membrane-derived 
arachidonic acid and local PG production has 
hormone-like effects. Two COX isoforms are 
expressed in human tissues: the constitutively 
expressed COX-1 isoform exists in most 
tissues while the COX-2 isoform is strongly 
induced during the inflammatory response, 
including pathological conditions of chronic 
inflammation and colon cancer.2 Among 
Abstract
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) and is a widely used medication. One 
indication of NSAID use is long-term chemoprevention to decrease the risk of developing various 
types of cancer, in particular colorectal cancer. The molecular mechanism behind the antitumour 
properties of NSAID has been largely attributed to inhibition of the enzyme cyclooxygenase. In this 
review article, the authors highlight that additional mechanisms of NSAID, especially ibuprofen, 
action exist that are related to cell signalling and the modulation of gene expression, including 
alternative splicing. For example, the authors describe how ibuprofen inhibits expression of the 
tumour-related splicing variant RAC1b, which is overexpressed in a specific subset of colorectal 
tumours. The mechanism involves changes in the phosphorylation of splicing factors that regulate this 
alternative splicing event. According to recent studies, ibuprofen interferes with signal transmission 
via protein kinases, a process which is frequently altered in cancer cells. 
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different COX-2-derived products, the highest 
PGE2 levels are found in tumours and affect 
various processes, including cell proliferation 
and apoptosis.3 In normal physiology, PGE2 
plays a role in the maintenance of the 
gastrointestinal mucosa regulating processes, 
such as mucus secretion and blood vessel 
dilation.4 Thus, prolonged NSAID treatment 
can lead to side effects, including intestinal 
bleeding. Most NSAID, including ibuprofen, inhibit 
both COX isoforms. 
Prophylactic use of NSAID has been 
documented to reduce the risk of dying from 
colorectal cancer.5-9 For example, a 300 mg daily 
dose of aspirin over a period of 10 years revealed 
a statistically significant protective effect.7,10,11 
A similar risk reduction was reported with a 
daily ibuprofen dose of 200 mg8,11-19 for various 
tumour types: 51% reduction in risk for colon, 
72% for breast, 62% for prostate, and 59% for 
lung cancer.19 
HOW DOES IBUPROFEN PREVENT 
CANCER? 
Accumulating evidence has revealed that 
inflammation promotes tumourigenesis,20,21 
in particular when the tissue is under chronic 
inflammatory conditions. Within the tumour 
microenvironment, inflammatory cells exchange 
signals with tumour cells. Stromal cells secrete 
survival factors for tumour cells while tumour 
cells produce cytokines, which trigger the 
proteolytic remodelling of the extracellular 
matrix by stromal cells, or the formation of 
new blood vessels.20,22 Ibuprofen inhibits COX 
activity and the subsequent generation of 
proinflammatory PG; this action is thought 
to underlie the chemopreventive effect of 
ibuprofen. PGE2, for example, activates G protein-
coupled PGE2 receptors that stimulate various 
signalling pathways involved in cell proliferation 
and survival.23,24 
In this article, the authors review additional 
mechanisms of action that are independent 
of COX-2 inhibition with the aim of increasing 
awareness that the clinical effects of ibuprofen 
can be mediated by several cellular processes. 
The presented evidence was retrieved from the 
PubMed search engine using “ibuprofen AND 
cancer” as the search term. Studies reporting 
COX-independent effects, including those 
conducted in the authors’ laboratory, were 
selected for review.
ADDITIONAL MECHANISMS THROUGH 
WHICH IBUPROFEN INHIBITS TUMOUR 
CELLS
In 2015, Matos and Jordan25 reviewed the 
treatment of  cancer cells with  ibuprofen. 
HCT-116 colorectal cells do not express COX-
2, but the treatment with 2 mMol/L ibuprofen 
produced proapoptotic effects.26 Ibuprofen at 
a low concentration of 100 µMol was further 
identified as a direct and COX-independent 
ligand of peroxisome proliferator-activated 
receptor gamma (PPARγ),27 and was shown 
to stimulate its nuclear activity in rat models of 
colon cancer formation.28 Thus, the proapoptotic 
action observed for ibuprofen may in part 
result from PPARγ activation, which leads 
to the downregulation of the antiapoptotic 
transcription factor NFκB.28 
Another COX-independent cellular response 
following ibuprofen treatment was reported to 
involve P75NTR, a member of the TNF receptor 
superfamily. Treatment of cancer cells with 1 
mMol/L ibuprofen resulted in a p38 mitogen-
activated protein kinase pathway-dependent 
stabilisation of p75NTR mRNA stability, leading 
to increased expression levels29 and induction of 
apoptosis and growth suppression.30 
A similar apoptosis-promoting action was 
reported in HCT116 cells, when ibuprofen 
treatment (1.5 mM for 24 hours) was found to 
sensitise these cells against the TNF-related 
apoptosis-inducing ligand.31 The underlying 
mechanism involved expression of the membrane 
receptor for TNF-related apoptosis-inducing 
ligand: death receptor 5, another member of the 
TNF receptor superfamily. 
Ibuprofen treatment (1 mMol/L for 24 hours) 
was further reported to significantly reduce 
the nuclear levels of β-catenin in SW480 and 
DLD-1 colorectal tumour cells. Consistently, the 
expression of one of its transcriptional targets, 
the pro-proliferative cyclin D1 gene, was 
suppressed.32 Although the underlying 
mechanism remains to be determined, this 
effect of ibuprofen seems of special interest for 
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colorectal cancer prevention because excessive 
β-catenin signalling can cause inappropriate 
growth stimulation of colon mucosa stem cells.33 
Concurrent to the effect on β-catenin signalling, 
ibuprofen also interfered directly with the 
NFκB pathway. A rapid effect of ibuprofen 
treatment observed in cells is the inhibitory 
phosphorylation of GSK-3β at serine 9.32 This 
modification was found to negatively regulate 
NFκB signalling, at a step downstream of the 
degradation of its inhibitor protein IkBα, and to 
suppress the expression of anti-apoptotic NFκB 
target genes, such as BCL2 and BIRC5.
Other examples for COX-independent effects 
of 100 µMol ibuprofen include the inhibition of 
integrin expression in neutrophils34 or the 
caspase-mediated release of proinflammatory 
cytokines in HCT-116 and HeLa cells.35 
IBUPROFEN, ALTERNATIVE SPLICING, 
AND CANCER
Cancer cells differ in their gene expression 
programme from their corresponding 
differentiated normal cells. Besides 
transcriptional regulation at gene promoters, 
the past 15 years have clearly revealed that 
alternative splicing serves as a significant 
mechanism for the regulation of gene 
expression. For example, alternative splicing 
generates transcript variants that can either 
be non-functional and rapidly degraded 
or be translated into protein isoforms with 
different, sometimes antagonistic, functional 
properties due to differential use of functional 
protein domains.36,37 
Recently, inhibition of the alternative splicing 
variant RAC1b was identified as another COX-
independent effect of ibuprofen.38 Colon 
inflammation was shown as one trigger for 
increased expression of the tumour-related 
RAC1b protein, a splice variant of the small 
GTPase RAC1. RAC1b protein contains an 
additional domain encoded by a 57 base pair-
long alternative exon (exon 3b), which confers 
increased protein activation, generating a 
hyperactive variant able to stimulate NFκB 
signalling.39-42 When colorectal cells were treated 
with ibuprofen, but not with aspirin or flurbiprofen, 
both the mRNA and protein levels of RAC1b 
were markedly reduced in vitro and in vivo.38 
Whereas many studies on the effect of NSAID 
on tumour cell viability used concentrations 
of up to 2 mMol/L,43 the effect of ibuprofen on 
alternative splicing of RAC1b was observed at 
low doses of 100 µMol. Interestingly, ibuprofen 
inhibited RAC1b-positive HT29 colorectal cells 
more than normal colonocytes and also affected 
their growth as subcutaneous tumour xenografts 
in mice. The inhibitory effect of ibuprofen could 
be rescued when a splicing-independent RAC1b 
cDNA sequence was expressed in HT29 cell.38 
This suggests that ibuprofen acts directly on the 
alternative splicing event. 
Another report on the modulation of alternative 
splicing was obtained when prostate cancer 
cells received combined treatment of ibuprofen 
and epigallocatechin-3-gallate (EGCG), a green 
tea component with anticarcinogenic properties 
that promotes G0/G1 cell cycle arrest and 
apoptosis. In this case, the balance between 
anti and proapoptotic splicing variants of BCL-X 
and MCL-1 was shifted towards the shorter and 
proapoptotic BCL-X(S) or MCL-1(S) variants.44 
Although the mechanism was not fully identified, 
it involves activation of protein phosphatase PP1, 
which is known to dephosphorylate regulatory 
proteins involved in pre-mRNA splicing. 
MECHANISM OF SPLICING 
MODULATION BY IBUPROFEN
When protein-coding genes are expressed 
in human cells, RNA polymerase 2 generates 
a primary transcript, the pre-mRNA, which 
contains coding exons separated by intronic 
sequences. While transcription  is ongoing, 
conserved nucleotide sequences around 
each exon–intron junction are recognised 
by the spliceosome, a macromolecular 
machinery involving five small nuclear 
ribonucleoprotein particles (U1, U2, U4, U5, 
and U6 small nuclear ribonucleoprotein),45,46 
which then removes introns during the process 
of mRNA splicing. The function of the 
spliceosome is assisted by splice enhancer 
or silencer elements, short sequences found 
in exons or introns, which either promote or 
inhibit productive recognition of a given exon 
by the spliceosome. Splicing factors recognise 
these splice enhancer or silencer elements, 
which mostly belong to the serine and arginine 
rich protein family or the heterogeneous 
nuclear ribonucleoproteins. They often act 
antagonistically, so that the modulation of 
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binding provides a mechanism that allows 
inclusion or skipping of alternative exon and 
thus the generation of variant transcripts. 
Altogether, the set of splicing factors expressed 
in a given cell and their relative expression levels 
in the cell nucleus operate in a combinatorial 
mode to regulate alternative splicing. 
In the case of RAC1b, alternative splicing is 
regulated by an enhancer element in exon 3b, 
which is recognised by the splicing factor SRSF1, 
and an adjacent silencer element recognised by 
SRSF3.47 
Figure 1: Effect of ibuprofen on subcellular localisation of protein kinase SRPK1. 
HT29 colorectal cells were incubated for 48 hours with either a DMSO control solvent, 500 µM ibuprofen, or 500 
µM aspirin and then fixed for immunofluorescence microscopy. Shown is the coloured overlay of three confocal 
immunofluorescence images (left), which detected cell nuclei in blue (DAPI), the localisation of endogenous 
SRPK1 protein in green (anti-SRPK1, BD Biosciences, San Jose, California, USA), and the actin cytoskeleton in red 
(Phalloidin-Texas Red). The nucleus and cytoplasm distribution of the three fluorescent signals was analysed along 
optical sections (yellow lines) across several cells by plotting pixel intensities along the traced path (right graphs). In 
control and aspirin-treated cells, SRPK1 signals (green) were localised both to the cytosol and the cell nucleus (blue); 
however, in ibuprofen-treated cells, nuclear signals for SRPK1 are nearly absent.
AU: arbitrary units; ASA: aspirin; DAPI: 4',6-diamidino-2-phenylindole; DMSO: dimethyl sulfoxide; IBU: ibuprofen; 
SRPK1: serine/threonine-protein kinase.
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Figure 2: Schematic representation of the cellular pathways linking ibuprofen to the cyclooxygenase-independent 
modulation of alternative splicing.
Following stimulation of receptor tyrosine kinases, the PI3K becomes activated and leads to phosphorylation of 
SRPK1, which enters the nucleus and phosphorylates the splicing factor SRSF1. SRSF1 binds to specific recognition 
motifs on nascent pre-mRNA transcribed by RNA polymerase 2, thus affecting alternative splicing decisions. In 
a parallel pathway, Wnt ligands stimulate their plasma membrane receptor leading to inhibition of the β-catenin 
destruction complex and accumulation of a cytosolic β-catenin/TCF4 complex. This complex enters the nucleus 
and binds to gene promoters, including that of splicing factor SRSF3, the expression levels of which determine the 
outcome of specific splicing events. Examples of splicing variants affected by these pathways are RAC1b, MCL1, and 
BCLX. Question marks indicate that the molecular mechanism is still unknown.
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In human colorectal cells, the availability of 
SRSF1 in the nucleus is the main factor regulating 
inclusion or skipping of exon 3b.48 
One mechanism through which ibuprofen 
does affect alternative splicing in cells is 
the phosphorylation status of SRSF1. Cell 
fractionation and immunoblot experiments 
revealed that ibuprofen treatment caused a 
reduction in SRSF1 phosphorylation (unpublished 
data). By contrast, aspirin treatment had no 
such effect on SRSF1. This showed that the 
inhibitory effect of ibuprofen on RAC1b splicing 
involved post-translational regulation of SRSF1 
subcellular localisation.48
The main protein kinase responsible for SRSF1 
phosphorylation is SRPK1, which is found both 
in the cytoplasm and in the cell nucleus.49,50 This 
process is, in part, controlled by growth factor 
receptor signalling.51 As shown and described 
in Figure 1, the authors observed that ibuprofen 
treatment induced translocation of SRPK1 
from the nucleus into the cytoplasm, and this 
correlated with reduced levels of SRSF1 
phosphorylation and RAC1b protein as detected 
in whole cell lysates by western blot. No such 
effect was observed when cells were treated with 
aspirin under the same conditions, underlining 
the COX-independent action of ibuprofen 
and the specificity of its effect on splicing 
factor modulation.
Another mechanism through which ibuprofen 
can regulate splicing is the transcriptional 
modulation of splicing factor-encoding genes. 
The splicing factor SRSF3, for example, 
was previously described to be a direct 
transcriptional target for β-catenin/TCF 
signalling and ibuprofen has been found 
to downregulate β-catenin/TCF signalling 
in colorectal cells.52 A reduction in SRSF3 
transcription and the consequent decrease 
in its nuclear levels will affect a variety of 
splicing variants. 
Further research may unravel that, besides 
SRSF1 and SRSF3, other splicing factors are 
also modulated by ibuprofen treatment, either 
by  regulation of their expression levels, their 
subcellular localisation, or their RNA-binding 
activity. These effects will most likely also 
include COX-dependent mechanisms as many 
of the PGE2 stimulated pathways23,24 have 
been described to affect alternative splicing 
regulation.53 It can thus be expected that 
ibuprofen treatment will affect a larger set 
of alternative splicing events in cancer cells 
and that these contribute to the described 
antiproliferative and proapoptotic effects.
CONCLUSION
Although ibuprofen has been used for 
chemopreventive therapies against cancers in 
the gastrointestinal tract, our understanding 
of the molecular mechanisms underlying 
the antineoplastic activity of ibuprofen is 
still rudimentary. Recently described cellular 
pathways linking ibuprofen to the COX-
independent modulation of alternative 
splicing are summarised in Figure 2. A better 
characterisation of its target molecules and their 
signalling pathways may provide opportunities 
for precision medicine approaches in cancer 
therapy or chemoprevention regimens. For 
example, the inhibitory effect on alternative 
splicing of RAC1b may benefit a subgroup of 
colorectal cancer patients characterised by 
serrated polyp morphology, BRAF mutation, and 
RAC1b overexpression. However, the deregulation 
of splicing factor SRSF1, which was described 
in this case, is most likely only the tip of the 
iceberg. It is now known that deregulation of 
splicing factors will inevitably affect a network 
of alternative splicing changes and this can be 
expected to have significant impact on cancer 
cell biology. A more systematic study with 
genome-wide determination of transcriptome 
changes should clarify the therapeutic 
opportunities that may arise from the COX-
independent action of ibuprofen.
AKT: protein kinase B; APC: adenomatous polyposis coli; GSK: glycogen synthase kinase; MCL1: myeloid Cell 
Leukemia Sequence 1; PIP2: phosphatidylinositol 4,5-bisphosphate; PIP3: phosphatidylinositol (3,4,5)-trisphosphate; 
PI3K: phosphoinositide 3-kinases; RAC1: Ras-related C3 botulinum toxin substrate 1: RP2: RNA polymerase 2; RTK: 
receptor tyrosine kinases; SRPK1: serine/threonine-protein kinase; SRSF: serine and arginine rich splicing factor; 
TCF4: transcription factor 4; Wnt: wingless/integrated.
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